MA46762A - Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm - Google Patents
Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnmInfo
- Publication number
- MA46762A MA46762A MA046762A MA46762A MA46762A MA 46762 A MA46762 A MA 46762A MA 046762 A MA046762 A MA 046762A MA 46762 A MA46762 A MA 46762A MA 46762 A MA46762 A MA 46762A
- Authority
- MA
- Morocco
- Prior art keywords
- rna
- improved process
- lipid nanoparticles
- nanoparticles loaded
- preparing lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
- C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420413P | 2016-11-10 | 2016-11-10 | |
| US201762580155P | 2017-11-01 | 2017-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46762A true MA46762A (fr) | 2019-09-18 |
Family
ID=60782328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046762A MA46762A (fr) | 2016-11-10 | 2017-11-10 | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180153822A1 (fr) |
| EP (1) | EP3538073A1 (fr) |
| JP (2) | JP7738979B2 (fr) |
| AU (1) | AU2017357758B2 (fr) |
| CA (1) | CA3041345A1 (fr) |
| MA (1) | MA46762A (fr) |
| WO (1) | WO2018089801A1 (fr) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| BR112016030852A2 (pt) * | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| EA201991747A1 (ru) * | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| EP3595713A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin contre le virus respiratoire syncytial |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3675817A1 (fr) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
| RS67724B1 (sr) * | 2017-10-20 | 2026-03-31 | BioNTech SE | Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju |
| US11939601B2 (en) | 2017-11-22 | 2024-03-26 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| EP3746090A4 (fr) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | Vaccins à base d'arn contre le vrs |
| US20210137840A1 (en) | 2018-04-25 | 2021-05-13 | Ethris Gmbh | Lipid-based formulations for the delivery of rna |
| AU2019271132B2 (en) * | 2018-05-15 | 2026-02-05 | Translate Bio, Inc. | Subcutaneous delivery of messenger RNA |
| US11964051B2 (en) | 2018-05-16 | 2024-04-23 | Translate Bio, Inc. | Ribose cationic lipids |
| JP7488193B2 (ja) | 2018-05-24 | 2024-05-21 | トランスレイト バイオ， インコーポレイテッド | チオエステルカチオン性脂質 |
| WO2019232208A1 (fr) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Lipides cationiques comprenant une fraction stéroïdienne |
| CA3101454A1 (fr) * | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Vaccins a arn messager et leurs utilisations |
| US12240824B2 (en) | 2018-05-30 | 2025-03-04 | Translate Bio, Inc. | Vitamin cationic lipids |
| CA3101484A1 (fr) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Lipides cationiques de phosphoesters |
| JP7422977B2 (ja) | 2018-07-23 | 2024-01-29 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａ用乾燥粉末製剤 |
| WO2020035460A1 (fr) * | 2018-08-14 | 2020-02-20 | Ethris Gmbh | Formulations à base de lipides contenant des sels pour l'administration d'arn |
| SG11202101778TA (en) * | 2018-08-24 | 2021-03-30 | Flagship Pioneering Innovations Vi Llc | Modified plant messenger packs and uses thereof |
| KR20210091120A (ko) | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
| EP3849617A1 (fr) | 2018-09-14 | 2021-07-21 | Translate Bio, Inc. | Compositions et méthodes de traitement de l'acidémie méthylmalonique |
| WO2020061295A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg de haute pureté et leurs utilisations |
| CA3113025A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg et leurs utilisations |
| WO2020061457A1 (fr) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Préparation de nanoparticules lipidiques et leurs méthodes d'administration |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CA3112837A1 (fr) | 2018-10-19 | 2020-04-23 | Translate Bio, Inc. | Encapsulation sans pompe d'arn messager |
| AU2019376660B2 (en) | 2018-11-09 | 2025-06-26 | Translate Bio, Inc. | 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities |
| EP3876914A2 (fr) | 2018-11-09 | 2021-09-15 | Translate Bio, Inc. | Thérapie par l'arn messager pour le traitement des maladies oculaires |
| CA3119449A1 (fr) * | 2018-11-12 | 2020-05-22 | Translate Bio, Inc. | Methodes pour induire une tolerance immunitaire |
| JP2022516356A (ja) | 2019-01-07 | 2022-02-25 | トランスレイト バイオ， インコーポレイテッド | 原発性線毛機能不全症の治療のための組成物および方法 |
| CN119700703A (zh) * | 2019-01-17 | 2025-03-28 | 佐治亚技术研究公司 | 含有氧化的胆固醇的药物递送系统 |
| CN118697900A (zh) * | 2019-01-31 | 2024-09-27 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| US20220177423A1 (en) | 2019-04-18 | 2022-06-09 | Translate Bio, Inc. | Cystine cationic lipids |
| US20220233444A1 (en) | 2019-04-22 | 2022-07-28 | Translate Bio, Inc. | Thioester cationic lipids |
| WO2020227085A1 (fr) | 2019-05-03 | 2020-11-12 | Translate Bio, Inc. | Lipides cationiques di-thioesters |
| CA3140423A1 (fr) * | 2019-05-14 | 2020-11-19 | Translate Bio, Inc. | Procede ameliore de preparation de nanoparticules lipidiques chargees d'arnm |
| WO2020243540A1 (fr) | 2019-05-31 | 2020-12-03 | Translate Bio, Inc. | Lipides macrocycliques |
| WO2020257611A1 (fr) | 2019-06-21 | 2020-12-24 | Translate Bio, Inc. | Lipides cationiques comprenant une fraction hydroxy |
| CA3144457A1 (fr) | 2019-06-21 | 2020-12-24 | Translate Bio, Inc. | Lipides a base de tricine et d'acide citrique |
| US20230181483A1 (en) * | 2019-07-08 | 2023-06-15 | Translate Bio, Inc. | Improved mrna-loaded lipid nanoparticles and processes of making the same |
| CA3146675A1 (fr) | 2019-07-23 | 2021-01-28 | Translate Bio, Inc. | Compositions stables de nanoparticules lipidiques chargees en arnm et leurs procedes de fabrication |
| EP4031662A1 (fr) | 2019-09-20 | 2022-07-27 | Translate Bio, Inc. | Arnm codant pour cftr modifiée |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| CN115515559B (zh) | 2019-12-20 | 2026-03-24 | 翻译生物公司 | 信使rna的直肠递送 |
| JP2023508881A (ja) * | 2019-12-20 | 2023-03-06 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス |
| WO2021142245A1 (fr) | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Composés, compositions pharmaceutiques et méthodes pour moduler l'expression de la muc5b dans des cellules et des tissus pulmonaires |
| CA3169669A1 (fr) * | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Procedes de preparation de nanoparticules lipidiques |
| US20210324369A1 (en) | 2020-02-10 | 2021-10-21 | Translate Bio, Inc. | Methods and compositions for messenger rna purification |
| AU2021224892A1 (en) | 2020-02-18 | 2022-10-13 | Translate Bio, Inc. | Improved processes for in vitro transcription of messenger RNA |
| CN115427021A (zh) * | 2020-02-25 | 2022-12-02 | 翻译生物公司 | 制备负载mrna的脂质纳米颗粒的改进方法 |
| CN115667207B (zh) | 2020-04-01 | 2025-09-16 | 翻译生物公司 | 基于酚酸脂质的阳离子脂质 |
| EP4146265A1 (fr) | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Séquences nucléotidiques optimisées codant pour des antigènes du sras-cov-2 |
| WO2021226468A1 (fr) | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Compositions améliorées de thérapie par arnm de la cftr |
| EP4146680A1 (fr) | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Composition et méthodes de traitement d'une dyskinésie ciliaire primitive |
| US12514932B2 (en) | 2020-05-14 | 2026-01-06 | Translate Bio, Inc. | PEG lipidoid compounds |
| JP2023526284A (ja) | 2020-05-15 | 2023-06-21 | トランスレイト バイオ， インコーポレイテッド | ｍＲＮＡ送達のための脂質ナノ粒子製剤 |
| EP4192432A1 (fr) * | 2020-08-06 | 2023-06-14 | ModernaTX, Inc. | Procédés de préparation de nanoparticules lipidiques |
| WO2022066678A1 (fr) | 2020-09-23 | 2022-03-31 | Translate Bio, Inc. | Lipides cationiques à base de tes |
| IL301536A (en) | 2020-09-23 | 2023-05-01 | Translate Bio Inc | Cationic lipids based on piperazine |
| KR20230087536A (ko) | 2020-10-12 | 2023-06-16 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 프로세스 |
| US20220133631A1 (en) | 2020-10-12 | 2022-05-05 | Translate Bio, Inc. | Process of preparing ice-based lipid nanoparticles |
| EP4228658A4 (fr) * | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | Lipides ionisables et procédés de fabrication et d'utilisation associés |
| WO2022099003A1 (fr) | 2020-11-06 | 2022-05-12 | Sanofi | Nanoparticules lipidiques pour l'administration de vaccins à arnm |
| AU2021373892A1 (en) | 2020-11-09 | 2023-07-06 | Translate Bio, Inc. | Improved compositions for delivery of codon-optimized mrna |
| EP4313115A1 (fr) | 2021-03-25 | 2024-02-07 | Translate Bio, Inc. | Séquences nucléotidiques optimisées codant pour le domaine extracellulaire de la protéine ace2 humaine ou une portion de celle-ci |
| JP2024515668A (ja) | 2021-04-19 | 2024-04-10 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａの送達のための改善された組成物 |
| EP4355308A1 (fr) | 2021-06-18 | 2024-04-24 | Sanofi | Vaccins multivalents contre la grippe |
| JP2024527541A (ja) | 2021-07-01 | 2024-07-25 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａの送達のための組成物 |
| WO2023009422A1 (fr) * | 2021-07-26 | 2023-02-02 | Modernatx, Inc. | Procédés de préparation de compositions de nanoparticules lipidiques pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4422698A1 (fr) | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| MX2024005462A (es) | 2021-11-05 | 2024-05-22 | Sanofi Sa | Vacuna de arn del virus respiratorio sincitial. |
| WO2023086893A1 (fr) | 2021-11-10 | 2023-05-19 | Translate Bio, Inc. | Composition et méthodes de traitement de la dyskinésie ciliaire primitive |
| JP2024542635A (ja) | 2021-11-30 | 2024-11-15 | サノフィ パスツール インコーポレイテッド | ヒトメタニューモウイルスワクチン |
| JP2025500880A (ja) | 2021-12-17 | 2025-01-15 | サノフイ | ライム病ｒｎａワクチン |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023178167A1 (fr) | 2022-03-16 | 2023-09-21 | Translate Bio, Inc. | Lipides cationiques à base de pipérazine asymétrique |
| US20250263385A1 (en) | 2022-04-13 | 2025-08-21 | Sanofi | "Good" buffer-based cationic lipids |
| CA3256624A1 (fr) | 2022-05-06 | 2023-11-09 | Sanofi | Séquences de signaux pour vaccins à base d'acides nucléiques |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| US20250320519A1 (en) | 2022-05-30 | 2025-10-16 | Shanghai Circode Biomed Co., Ltd. | Synthetic circular rna compositions and methods of use thereof |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| EP4565209A1 (fr) | 2022-08-04 | 2025-06-11 | Sanofi Pasteur Inc. | Évaluation quantitative d'encapsulation d'arn |
| JP2025529906A (ja) | 2022-08-22 | 2025-09-09 | ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | コロナウイルスに対するワクチン |
| EP4608442A1 (fr) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Vaccin à base d'acide nucléique |
| KR20250099727A (ko) | 2022-11-04 | 2025-07-02 | 사노피 파스퇴르 인크 | 호흡기 세포융합 바이러스 rna 백신접종 |
| WO2024102677A1 (fr) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Compositions d'arn circulaire |
| WO2024126809A1 (fr) | 2022-12-15 | 2024-06-20 | Sanofi | Arnm codant pour une particule de type virus de la grippe |
| EP4637813A1 (fr) | 2022-12-20 | 2025-10-29 | Sanofi Pasteur | Vaccin contre l'arnm de rhinovirus |
| WO2024160826A1 (fr) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions et procédés |
| CN120813371A (zh) | 2023-03-02 | 2025-10-17 | 赛诺菲巴斯德有限公司 | 用于在衣原体病的治疗中使用的组合物 |
| WO2024184500A1 (fr) | 2023-03-08 | 2024-09-12 | CureVac SE | Nouvelles formulations de nanoparticules lipidiques pour l'administration d'acides nucléiques |
| US12502424B2 (en) | 2023-05-05 | 2025-12-23 | Sanofi Pasteur Inc. | Compositions for use in treatment of acne |
| WO2024231565A1 (fr) | 2023-05-10 | 2024-11-14 | Sanofi | Vaccins à arnm respiratoire combinés |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
| CN121568920A (zh) | 2023-06-12 | 2026-02-24 | 赛诺菲 | 具有芳香族头基团的基于三(羟甲基)甲基甘氨酸和柠檬酸的阳离子脂质 |
| MX2025015001A (es) | 2023-06-12 | 2026-02-03 | Sanofi Sa | Lipidos cationicos basados en tricina y acido citrico |
| EP4724456A1 (fr) | 2023-06-12 | 2026-04-15 | Sanofi | Lipides cationiques à base de stérol avec des groupes de tête aromatiques |
| EP4734960A1 (fr) | 2023-06-28 | 2026-05-06 | Sanofi Pasteur Inc. | Analogues de stérol dans des formulations de nanoparticules lipidiques |
| CN121752576A (zh) | 2023-06-28 | 2026-03-27 | 赛诺菲巴斯德有限公司 | 用于核酸递送的辅助脂质 |
| WO2025003759A1 (fr) | 2023-06-28 | 2025-01-02 | Sanofi | Lipides ionisables à base de dianhydrohexitol pour la délivrance d'acides nucléiques |
| AU2024291595A1 (en) | 2023-07-19 | 2026-03-05 | Sanofi | Porphyromonas gingivalis antigenic constructs |
| WO2025051975A1 (fr) | 2023-09-06 | 2025-03-13 | Sanofi | Polypeptides d'hémagglutinine de la grippe b modifiés et acides nucléiques et leurs utilisations |
| WO2025061967A1 (fr) | 2023-09-20 | 2025-03-27 | Sanofi | Lipides cationiques à base de tampons de good pour la délivrance d'acides nucléiques |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| CN121219273A (zh) * | 2023-11-02 | 2025-12-26 | 深圳厚存纳米药业有限公司 | 脂质和脂质纳米颗粒制剂 |
| WO2025101862A1 (fr) | 2023-11-08 | 2025-05-15 | Axelyf ehf. | Liants d'anticorps à domaine unique de myc |
| WO2025104351A1 (fr) | 2023-11-17 | 2025-05-22 | Sanofi Pasteur Inc. | Dosages par clhp pour détecter de multiples constructions d'arnm |
| WO2025117969A1 (fr) | 2023-12-01 | 2025-06-05 | Orna Therapeutics, Inc. | Procédé de fabrication de nanoparticules lipidiques |
| WO2025134071A1 (fr) | 2023-12-22 | 2025-06-26 | Sanofi | Lipides ionisables à base d'acide malique et d'acide glutarique |
| WO2025141521A1 (fr) | 2023-12-29 | 2025-07-03 | Sanofi | Lipides comportant des fractions dendritiques |
| WO2025166238A1 (fr) | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Lipides de polyéthylène glycol à détachement rapide |
| WO2025196065A1 (fr) | 2024-03-20 | 2025-09-25 | Sanofi | Nouveaux lipides à base d'homocystéine et leur utilisation pour l'administration d'acides nucléiques |
| WO2025210592A1 (fr) | 2024-04-05 | 2025-10-09 | Sanofi Pasteur Inc. | Dosages de contrôle de qualité de lnp-arnm de cellules musculaires |
| WO2025261607A1 (fr) | 2024-06-21 | 2025-12-26 | BioNTech SE | Particules, compositions et procédés |
| WO2026006524A2 (fr) | 2024-06-26 | 2026-01-02 | Sanofi Pasteur Inc. | Lipides cationiques de bis-ester et d'amide |
| WO2026003373A1 (fr) | 2024-06-28 | 2026-01-02 | Sanofi | Lipides cationiques à base de lipide d'acide phénolique |
| WO2026008743A1 (fr) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Polymère polyanionique soluble dans l'eau en tant qu'adjuvant pour acide nucléique formulé par un support |
| WO2026027730A1 (fr) | 2024-07-31 | 2026-02-05 | Sanofi | Polypeptides d'hémagglutinine de la grippe h5 modifiés et acides nucléiques et leurs utilisations |
| WO2026033123A1 (fr) | 2024-08-08 | 2026-02-12 | Sanofi Pasteur Inc. | Formulations de nanoparticules lipidiques pour l'administration d'arnm |
| WO2026053147A1 (fr) | 2024-09-05 | 2026-03-12 | Sanofi Pasteur Inc. | Lipides auxiliaires et compositions de lnp les comprenant |
| WO2026052773A1 (fr) | 2024-09-06 | 2026-03-12 | Sanofi | Polypeptides d'hémagglutinine de la grippe a modifiés et acides nucléiques et leurs utilisations |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| JP2599492B2 (ja) * | 1990-08-21 | 1997-04-09 | 第一製薬株式会社 | リポソーム製剤の製造法 |
| WO1993003709A1 (fr) * | 1991-08-16 | 1993-03-04 | Vical, Inc. | Composition et procede de traitement de la mucoviscidose |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| WO2000021370A1 (fr) * | 1998-10-14 | 2000-04-20 | University Of Kentucky Research Foundation | Systemes d'administration oligonucleotidique pour des camptothecines |
| WO2000029103A1 (fr) * | 1998-11-13 | 2000-05-25 | Optime Therapeutics, Inc. | Procede et dispositif de production de liposomes |
| BR0012624B1 (pt) * | 1999-07-15 | 2011-08-09 | métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos. | |
| US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
| EP1202714A1 (fr) * | 1999-07-16 | 2002-05-08 | Purdue Research Foundation | Lipides d'ether vinyliques avec des groupes de tetes hydrophiles clivables |
| CA2569664C (fr) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Arn interferant encapsule dans des lipides |
| CA2740000C (fr) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Lipides amines ameliores et procedes d'administration d'acides nucleiques |
| EP3269395A1 (fr) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Lipidoïdes aminoalcool et leurs utilisations |
| EP3318248B1 (fr) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines |
| CN102018672B (zh) * | 2010-11-29 | 2013-09-18 | 广州朗圣药业有限公司 | 一种水溶性药物的脂质体冻干组合物及其制备方法 |
| ES2795110T3 (es) | 2011-06-08 | 2020-11-20 | Translate Bio Inc | Lípidos escindibles |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| EP2787977A4 (fr) * | 2011-12-09 | 2015-05-06 | Univ California | Encapsulation liposomale de médicaments |
| WO2013143555A1 (fr) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| WO2014152211A1 (fr) * | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés |
| TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| AU2014340149B2 (en) * | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| JP2017507946A (ja) * | 2014-02-26 | 2017-03-23 | エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ | Ｒｎａを胃腸内投与するための組成物 |
| JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| EP3247363A4 (fr) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
| EP3247398A4 (fr) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| WO2017180917A2 (fr) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Compositions lipidiques et leurs utilisations pour l'administration intratumorale de polynucléotides |
-
2017
- 2017-11-10 AU AU2017357758A patent/AU2017357758B2/en active Active
- 2017-11-10 WO PCT/US2017/061113 patent/WO2018089801A1/fr not_active Ceased
- 2017-11-10 CA CA3041345A patent/CA3041345A1/fr active Pending
- 2017-11-10 EP EP17818338.0A patent/EP3538073A1/fr active Pending
- 2017-11-10 MA MA046762A patent/MA46762A/fr unknown
- 2017-11-10 US US15/809,680 patent/US20180153822A1/en not_active Abandoned
- 2017-11-10 JP JP2019524194A patent/JP7738979B2/ja active Active
-
2023
- 2023-06-02 US US18/328,206 patent/US20240041789A1/en active Pending
- 2023-08-31 JP JP2023141009A patent/JP2023166489A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018089801A1 (fr) | 2018-05-17 |
| AU2017357758A1 (en) | 2019-05-16 |
| JP7738979B2 (ja) | 2025-09-16 |
| US20240041789A1 (en) | 2024-02-08 |
| AU2017357758B2 (en) | 2023-11-16 |
| JP2019533707A (ja) | 2019-11-21 |
| JP2023166489A (ja) | 2023-11-21 |
| CA3041345A1 (fr) | 2018-05-17 |
| EP3538073A1 (fr) | 2019-09-18 |
| US20180153822A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46762A (fr) | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm | |
| EP3652186A4 (fr) | Procédé général et direct pour préparer des nanoparticules à structure organométallique fonctionnalisées par des oligonucléotides | |
| EP3525806A4 (fr) | Procédé de lyophilisation d'exosomes | |
| EP3331896A4 (fr) | Procédés de préparation d'acides biliaires et de leurs dérivés | |
| EP2841486A4 (fr) | Nanoparticules polymères et leur procédé de préparation | |
| EP3378869A4 (fr) | Procédé de production d'oligonucléotide | |
| MA71469A (fr) | Procédé de préparation d'oligomères morpholino de phosphorodiamidate | |
| MA52906A (fr) | Procédé de préparation d'amg 416 | |
| EP3006445A4 (fr) | Hydrogénosulfate d'inhibiteur de janus kinase (jak) et son procédé de préparation | |
| EP3383436A4 (fr) | Procédé amélioré de préparation de vert d'indocyanine | |
| EP3434262A4 (fr) | Procédé de préparation de microgranules à libération prolongée | |
| EP3398957A4 (fr) | Procédé de synthèse de l'ételcalcétide | |
| EP3381498A4 (fr) | Microaiguille et procédé pour la produire | |
| EP3398958A4 (fr) | Polyamino-acide, conjugué protéine-polyamino-acide et procédé de préparation correspondant | |
| EP2957576A4 (fr) | Procédé de préparation d'une résine superabsorbante | |
| EP3341359A4 (fr) | Procédé de préparation d'aprémilast | |
| EP2977448A4 (fr) | Procédé de préparation de chondrocytes | |
| EP2900084A4 (fr) | Procédé de préparation d'arôme naturel de b uf | |
| EP3766869A4 (fr) | Procédé simple de préparation d'avibactam | |
| EP3334777A4 (fr) | Procédé de revêtement d'articles | |
| EP3296282A4 (fr) | Procédé de production d'hydrohalofluorooléfines | |
| MA42423A (fr) | Procédé de préparation d'un revêtement | |
| EP3015479A4 (fr) | Procédé de préparation d'une résine superabsorbante | |
| EP3388424A4 (fr) | Procédé de préparation de médicaments lcz696 contre l'insuffisance cardiaque | |
| EP3513888A4 (fr) | Procédé de coulée continue |